|
1
|
Petera J, Sirak I, Beranek M, Vosmik M,
Drastikova M, Paulikova S and Soumarova R: Molecular predictive
factors of outcome of radiotherapy in cervical cancer. Neoplasma.
58:469–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu X, Fan W, Xu S and Zhou Y:
Sensitization to the cytotoxicity of cisplatin by transfection with
nucleotide excision repair gene xeroderma pigmentosun group a
antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res.
9:5874–5879. 2003.PubMed/NCBI
|
|
5
|
Guggenheim ER, Xu D, Zhang CX, Chang PV
and Lippard SJ: Photoaffinity isolation and identification of
proteins in cancer cell extracts that bind to platinum-modified
DNA. Chembiochem. 10:141–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang C and Lees-Miller SP: Detection and
repair of ionizing radiation-induced DNA double strand breaks: New
developments in nonhomologous end joining. Int J Radiat Oncol Biol
Phys. 86:440–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collis SJ, DeWeese TL, Jeggo PA and Parker
AR: The life and death of DNA-PK. Oncogene. 24:949–961. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burma S and Chen DJ: Role of DNA-PK in the
cellular response to DNA double-strand breaks. DNA Repair (Amst).
3:909–918. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lieber MR, Ma Y, Pannicke U and Schwarz K:
Mechanism and regulation of human non-homologous DNA end-joining.
Nat Rev Mol Cell Biol. 4:712–720. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goodwin JF and Knudsen KE: Beyond DNA
repair: DNA-PK function in cancer. Cancer Discov. 4:1126–1139.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Myint WK, Ng C and Raaphorst GP: Examining
the non-homologous repair process following cisplatin and radiation
treatments. Int J Radiat Biol. 78:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boeckman HJ, Trego KS and Turchi JJ:
Cisplatin sensitizes cancer cells to ionizing radiation via
inhibition of nonhomologous end joining. Mol Cancer Res. 3:277–285.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sears CR and Turchi JJ: Complex
cisplatin-double strand break (DSB) lesions directly impair
cellular non-homologous end-joining (NHEJ) independent of
downstream damage response (DDR) pathways. J Biol Chem.
287:24263–24272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhuang L, Yu SY, Huang XY, Gao QL, Xiong H
and Leng Y: Effect of Ku80 expression inhibition by RNA
interference on proliferation of cervical carcinoma cell line HeLa.
Ai Zheng. 26:252–257. 2007.PubMed/NCBI
|
|
15
|
Jayakumar S, Bhilwade HN, Pandey BN,
Sandur SK and Chaubey RC: The potential value of the neutral comet
assay and the expression of genes associated with DNA damage in
assessing the radiosensitivity of tumor cells. Mutat Res.
748:52–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valerie K and Povirk LF: Regulation and
mechanisms of mammalian double-strand break repair. Oncogene.
22:5792–5812. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Williams GJ, Hammel M, Radhakrishnan SK,
Ramsden D, Lees-Miller SP and Tainer JA: Structural insights into
NHEJ: Building up an integrated picture of the dynamic DSB repair
super complex, one component and interaction at a time. DNA Repair
(Amst). 17:110–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gullo C, Au M, Feng G and Teoh G: The
biology of Ku and its potential oncogenic role incancer. Biochim
Biophys Acta. 1765:223–234. 2006.PubMed/NCBI
|
|
19
|
Zhuang L, Cao Y, Xiong H, Gao Q, Cao Z,
Liu F, Qiu H, Yu S and Huang X: Suppression of DNA-PKcs and Ku80
individually and in combination: Different effects of radiobiology
in HeLa cells. Int J Oncol. 39:443–451. 2011.PubMed/NCBI
|
|
20
|
Melo J and Toczyski D: A unified view of
the DNA-damage checkpoint. Curr Opin Cell Biol. 14:237–245. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wieringa HW, van der Zee AG, de Vries EG
and van Vugt MA: Breaking the DNA damage response to improve
cervical cancer treatment. Cancer Treat Rev. 42:30–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fillingham J, Keogh MC and Krogan NJ:
GammaH2AX and its role in DNA double-strand break repair. Biochem
Cell Biol. 84:568–577. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Turchi JJ and Henkels K: Human Ku
autoantigen binds cisplatin-damaged DNA but fails to stimulate
human DNA-activated protein kinase. J Biol Chem. 271:13861–13867.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jensen R and Glazer PM:
Cell-interdependent cisplatin killing by Ku/DNA-dependent protein
kinase signaling transduced through gap junctions. Proc Natl Acad
Sci USA. 101:pp. 6134–6139. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moll U, Lau R, Sypes MA, Gupta MM and
Anderson CW: DNA-PK, the DNA-activated protein kinase, is
differentially expressed in normal and malignant human tissues.
Oncogene. 18:3114–3126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harima Y, Sawada S, Miyazaki Y, Kin K,
Ishihara H, Imamura M, Sougawa M, Shikata N and Ohnishi T:
Expression of Ku80 in cervical cancer correlates with response to
radiotherapy and survival. Am J Clin Oncol. 26:e80–e85. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pavón MA, Parreño M, León X, Sancho FJ,
Céspedes MV, Casanova I, Lopez-Pousa A, Mangues MA, Quer M,
Barnadas A and Mangues R: Ku70 predicts response and primary tumor
recurrence after therapy in locally advanced head and neck cancer.
Int J Cancer. 123:1068–1079. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hayashi J, Sakata KI, Someya M, Matsumoto
Y, Satoh M, Nakata K, Hori M, Takagi M, Kondoh A, Himi T and
Hareyama M: Analysis and results of Ku and XRCC4 expression in
hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol
Lett. 4:151–155. 2012.PubMed/NCBI
|
|
29
|
Ma Q, Li P, Xu M, Yin J, Su Z, Li W and
Zhang J: Ku80 is highly expressed in lung adenocarcinoma and
promotes cisplatin resistance. J Exp Clin Cancer Res. 31:992012.
View Article : Google Scholar : PubMed/NCBI
|
